Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know

Affiliations

Free article

Comment

Roberto Delgado-Bolton et al. J Nucl Med. 2018 Apr.

Free article

. 2018 Apr;59(4):715-716.

doi: 10.2967/jnumed.117.206946. Epub 2018 Feb 1.

¹ University of Southern California 2250 Alcazar St. CSC 102 Los Angeles, CA 90033 Email: jadvar@med.usc.edu.

No abstract available

Comment on

Appropriate Use Criteria for ¹⁸F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease.
Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L. Jadvar H, et al. J Nucl Med. 2017 Dec;58(12):2026-2037. doi: 10.2967/jnumed.117.197988. Epub 2017 Oct 12. J Nucl Med. 2017. PMID: 29025980 No abstract available.
Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know.
Kanoun S, Cottereau AS, Berriolo-Riedinger A, Meignan M, Casasnovas O, Courbon F, Kraeber-Bodéré F. Kanoun S, et al. J Nucl Med. 2018 Apr;59(4):714-715. doi: 10.2967/jnumed.117.205351. Epub 2017 Dec 21. J Nucl Med. 2018. PMID: 29269571 No abstract available.